About ozanimod
Sphingosine-1-phosphate receptor modulator
Used for
- Treats relapsing forms of multiple sclerosis in adults
- Treats moderately to severely active ulcerative colitis in adults
Usual adult dose
Multiple sclerosis: 0.23 mg once daily for 4 days, then 0.46 mg once daily for 3 days, then 0.92 mg once daily. Ulcerative colitis: same 7-day start, then 0.92 mg once daily.
Common side effects
- Upper respiratory infections
- Headache
- Increased liver enzymes
- Raised blood pressure
Important warnings
- Can slow heart rate, especially when starting treatment
- May increase serious infection risk; screening and blood tests are needed
- May cause macular edema or liver injury
- Can cause fetal harm; effective contraception is advised during treatment and for 3 months after stopping
Pregnancy
May cause fetal harm; generally avoided during pregnancy. Effective contraception is advised during treatment and for 3 months after stopping.
Breastfeeding
It is not known whether ozanimod passes into breast milk; discuss risks and benefits with a healthcare professional.
Interactions
- Avoid medicines that affect heart rhythm or slow heart rate unless specifically reviewed
- Avoid monoamine oxidase inhibitors
- Some medicines affecting CYP2C8 can change ozanimod levels
- Live vaccines should be avoided during treatment and for 3 months afterward
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.